Results 91 to 100 of about 124,093 (287)

Should phosphodiesterase 5 selective inhibitors be used for uterine relaxation?

, 2006
International audienceSildenafil citrate is a phosphodiesterase 5-selective inhibitor used successfully in treating erectile dysfunction. High doses of sildenafil can inhibit myometrial contractions.
Breuiller-Fouché, Michelle, Schmitz, Thomas, Méhats, Céline, Leroy, Marie-Josèphe, Cabrol, Dominique   +4 more
core   +1 more source

Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes

Biochemistry and Biophysics Reports, 2017
The use of liposomes to affect targeted delivery of pharmaceutical agents to specific sites may result in the reduction of side effects and an increase in drug efficacy. Since liposomes are delivered intravascularly, erythrocytes, which constitute almost
Elizabeth A. Bowles, Dimitri Feys, Nuran Ercal, Randy S. Sprague   +3 more
doaj   +1 more source

Traditional Chinese Medicine and Natural Products Targeting Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: Toward Precision Cardiometabolic Therapy

iNew Medicine, EarlyView.
Natural products and traditional Chinese medicine target metabolic pathways underlying right ventricular dysfunction in pulmonary arterial hypertension. Integrating multi‐omics, artificial intelligence, and systems biology may enable precision cardiometabolic therapies to restore right ventricular metabolism and improve clinical outcomes.
Yihao Wu, Zhehui Tang, Hongwei Yao
wiley   +1 more source

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility

Therapeutics and Clinical Risk Management, 2014
Eric G Katz,1 Ronny BW Tan,2 Daniel Rittenberg,1 Wayne J Hellstrom3 1Tulane University School of Medicine, New Orleans, LA, USA; 2Department of Urology, Tan Tock Seng Hospital, Singapore; 3Section of Andrology, Department of Urology, Tulane University ...
Katz EG, Tan RBW, Rittenberg D, Hellstrom WJ   +3 more
doaj  

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

iNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang   +4 more
wiley   +1 more source

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator

, 2018
Pulmonary arterial hypertension is a chronic and life-threatening disease that if left untreated is fatal. Current therapies include stimulating the nitric oxide–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate axis, improving the ...
null null, Hiroshi Watanabe
core   +1 more source

A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations

Brazilian Journal of Pharmaceutical Sciences, 2013
The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men.
Cristiane Franco Codevilla, Tamara dos Santos Castilhos, Ana Maria Bergold   +2 more
doaj  

Corticosterone and Mitochondrial Efficiency Are Associated With Changes in DNA Oxidative Damage During an Acute Stress Response in Leach's Storm‐Petrels (Hydrobates leucorhous)

Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, EarlyView.
ABSTRACT The ability of organisms to effectively respond to challenges is critical for survival. We investigated how an acute stressor affected corticosterone, mitochondrial function, and DNA oxidative damage in a wild population of Leach's storm‐petrels (Hydrobates leucorhous).
Kayla E. Lichtner, Jack K. Dziubek, Nicole A. Joseph, Sarah E. Chapman, Tori J. Chace, Dongxiao Sun, Zachary T. Bitzer, Antoine Stier, Robert A. Mauck, Patricia L. Jones, Mark F. Haussmann   +10 more
wiley   +1 more source

Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction

, 2005
Erectile dysfunction (ED) is a common medical condition that affects the sexual life of millions of men. At present, first-line oral pharmacotherapy for most patients with ED is a phosphodiesterase type 5 (PDE-5) inhibitor, of which three are currently ...
Antonino Saccà, Piero Montorsi, A. Saccà, A. Briganti, A. Salonia, P. Montorsi, Andrea Gallina, A. Gallina, Francesco Montorsi, F. Montorsi, Andrea Salonia, P. Rigatti, Alberto Briganti, Patrizio Rigatti   +13 more
core   +1 more source

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations

International Journal of General Medicine, 2014
Bader Alsaikhan, Khalid Alrabeeah, Serge CarrierMcGill University Health Centre, Montreal, Quebec, QC, CanadaAbstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age.
Alsaikhan B, Alrabeeah K, Carrier S
doaj